Search research articles
Contact Us
Filters
Showing results (71-80 of 161) with videos related to
Page
of 17
Sort By:
Neuro-Oncology Advances
|
August 13, 2025
Cerebrospinal fluid liquid biopsy guides differential diagnosis of relapsed medulloblastoma versus secondary glioma: A case report of a pediatric patient enrolled on a <i>PDGFRA</i> inhibitor trial
Tom T Fischer, Kendra K Maass, Melanie Schoof, et al.
Journal of Neuro-Oncology
|
October 7, 2020
Response to trametinib treatment in progressive pediatric low-grade glioma patients
Florian Selt, Cornelis M van Tilburg, Brigitte Bison, et al.
Cancers
|
June 19, 2024
Radiotherapy for Recurrent Medulloblastoma in Children and Adolescents: Survival after Re-Irradiation and First-Time Irradiation
Jonas E Adolph, Gudrun Fleischhack, Sebastian Tschirner, et al.
Acta Neuropathologica Communications
|
July 27, 2023
Mitochondrial DNA mutations in Medulloblastoma
Viktoria L E Funke, Sarah Sandmann, Viktoria Melcher, et al.
Molecular Cancer Therapeutics
|
May 27, 2020
A Cell-Based MAPK Reporter Assay Reveals Synergistic MAPK Pathway Activity Suppression by MAPK Inhibitor Combination in <i>BRAF</i>-Driven Pediatric Low-Grade Glioma Cells
Diren Usta, Romain Sigaud, Juliane L Buhl, et al.
Acta Neuropathologica
|
August 25, 2011
A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat
Till Milde, Susanne Kleber, Andrey Korshunov, et al.
The Journal of Clinical Investigation
|
May 24, 2008
CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors
Sergey V Shmelkov, Jason M Butler, Andrea T Hooper, et al.
Acta Neuropathologica
|
March 11, 2015
Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers
Andrey Korshunov, Marina Ryzhova, Volker Hovestadt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 10, 2010
TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma
Elke Pfaff, Marc Remke, Dominik Sturm, et al.
BMC Cancer
|
June 7, 2020
INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies
Cornelis M van Tilburg, Ruth Witt, Melanie Heiss, et al.
Page
of 17
Search research articles
Search
Showing results (71-80 of 161) with videos related to
Sort By:
Page
of 17
Neuro-Oncology Advances
|
August 13, 2025
Cerebrospinal fluid liquid biopsy guides differential diagnosis of relapsed medulloblastoma versus secondary glioma: A case report of a pediatric patient enrolled on a <i>PDGFRA</i> inhibitor trial
Tom T Fischer, Kendra K Maass, Melanie Schoof, et al.
Journal of Neuro-Oncology
|
October 7, 2020
Response to trametinib treatment in progressive pediatric low-grade glioma patients
Florian Selt, Cornelis M van Tilburg, Brigitte Bison, et al.
Cancers
|
June 19, 2024
Radiotherapy for Recurrent Medulloblastoma in Children and Adolescents: Survival after Re-Irradiation and First-Time Irradiation
Jonas E Adolph, Gudrun Fleischhack, Sebastian Tschirner, et al.
Acta Neuropathologica Communications
|
July 27, 2023
Mitochondrial DNA mutations in Medulloblastoma
Viktoria L E Funke, Sarah Sandmann, Viktoria Melcher, et al.
Molecular Cancer Therapeutics
|
May 27, 2020
A Cell-Based MAPK Reporter Assay Reveals Synergistic MAPK Pathway Activity Suppression by MAPK Inhibitor Combination in <i>BRAF</i>-Driven Pediatric Low-Grade Glioma Cells
Diren Usta, Romain Sigaud, Juliane L Buhl, et al.
Acta Neuropathologica
|
August 25, 2011
A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat
Till Milde, Susanne Kleber, Andrey Korshunov, et al.
The Journal of Clinical Investigation
|
May 24, 2008
CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors
Sergey V Shmelkov, Jason M Butler, Andrea T Hooper, et al.
Acta Neuropathologica
|
March 11, 2015
Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers
Andrey Korshunov, Marina Ryzhova, Volker Hovestadt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 10, 2010
TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma
Elke Pfaff, Marc Remke, Dominik Sturm, et al.
BMC Cancer
|
June 7, 2020
INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies
Cornelis M van Tilburg, Ruth Witt, Melanie Heiss, et al.
Page
of 17